{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.6","value":"122"},{"groupId":"OG001","spread":"51.8","value":"246"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Ceoi is the plasma concentration observed at the end of intravenous infusion.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Isatuximab 10 mg/kg IV infusion QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 112 weeks).","id":"OG000","title":"Phase 1, Cohort 1: Isatuximab 10 mg/kg"},{"description":"Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 137 weeks).","id":"OG001","title":"Phase 1, Cohort 2: Isatuximab 20 mg/kg"}],"paramType":"MEAN","populationDescription":"Analysis was performed on PK population that included all participants who gave their informed consent and received at least one dose (even incomplete) of Isatuximab; with data for at least 1 PK parameter available. Here, \"Overall number of participants analyzed\" = participants with available data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"End of infusion on Day 1 of Cycle 1","title":"Phase 1: Plasma Concentration Observed at the End of Intravenous Infusion (Ceoi) of Isatuximab","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter"}